More on ANGO
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $12.92 |
|
|||
| Open | $12.85 | ||||
| 52 Wk High | $17.64 | ||||
| 52 Wk Low | $9.71 | ||||
| Day High | $12.94 | ||||
| Day Low | $12.55 | ||||
| P/E | N/A | ||||
| EPS | $-0.07 | ||||
| Volume | 202,945 | ||||
- AngioDynamics to Report Fiscal 2026 Fourth Quarter and Full-Year Financial Results on July 14, 2026
- AngioDynamics gets FDA approval to study NanoKnife for BPH treatment
- AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
- AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
- AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Form SCHEDULE 13G/A ANGIODYNAMICS INC Filed by: Point72 Asset Management, L.P.
- AngioDynamics reports sustained prostate cancer treatment outcomes at 24 months
- AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
- Form 8-K ANGIODYNAMICS INC For: Apr 23
- Freedom Broker Starts AngioDynamics (ANGO) at Buy
Entities mentioned with ANGO
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- 13G | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Barclays | View Related Stories »
- Show More...
